Details:
Company announced completion GLPG2737 trial a CFTR inhibitor in patients with ADPKD. Primary objectives of trial is to assess the effect on growth of total kidney volume over 52 weeks compared to placebo as well as overall safety and tolerability.
Lead Product(s): GLPG2737
Therapeutic Area: Genetic Disease Product Name: GLPG2737
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 22, 2021